Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business ...

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological ...
Yahoo Finance

Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor ...

Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of ...